产品服务
信号通路
详细信息
推荐稀释比 ： IHC 1:200-1:1000;WB 1:500-1:2000;IF 1:200-1:1000;ELISA 1:5000-1:20000;
组成 ： PBS, 50% glycerol, 0.05% Proclin 300, 0.05%BSA
纯化工艺 ： Protein A
储存 ： -15°C to -25°C/1 year(Do not lower than -25°C
克隆性 ： Monoclonal
克隆号 ： PT1406R
抗原&靶点信息
特异性 ： Endogenous
基因名称 ： VHL
蛋白名称 ： Von Hippel-Lindau disease tumor suppressor
别名 ： VHL;Von Hippel-Lindau disease tumor suppressor;Protein G7;pVHL
背景：
von Hippel-Lindau tumor suppressor(VHL) Homo sapiens Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed. [provided by RefSeq, Jul 2008],
细胞定位 ： Disease:Defects in VHL are a cause of pheochromocytoma [MIM:171300]. The pheochromocytomas are catecholamine-producing, chromaffin tumors that arise in the adrenal medulla in 90% of cases. In the remaining 10% of cases, they develop in extra-adrenal sympathetic ganglia and may be referred to as "paraganglioma." Pheochromocytoma usually presents with hypertension. Approximately 10% of pheochromocytoma is hereditary. The genetic basis for most cases of non-syndromic familial pheochromocytoma is unknown.,Disease:Defects in VHL are a cause of renal cell carcinoma type 1 (RCC1) [MIM:144700]; also called hypernephroma or adenocarcinoma of kidney. Familial renal cell carcinoma syndromes form a group of diseases characterized by a predisposition to development of renal cell carcinomas (RCCs) with various histological subtypes.,Disease:Defects in VHL are the cause of erythrocytosis familial type 2 (ECYT2) [MIM:263400]; also called VHL-dependent polycythemia or Chuvash type polycythemia. ECYT2 is an autosomal recessive disorder characterized by an increase in serum red blood cell mass, hypersensitivity of erythroid progenitors to erythropoietin, increased erythropoietin serum levels, and normal oxygen affinity. Patients with ECYT2 carry a high risk for peripheral thrombosis and cerebrovascular events.,Disease:Defects in VHL are the cause of von Hippel-Lindau disease (VHLD) [MIM:193300]. VHLD is a dominantly inherited familial cancer syndrome characterized by the development of retinal angiomatosis, cerebellar and spinal hemangioblastoma, renal cell carcinoma (RCC), phaeochromocytoma and pancreatic tumors. VHL type 1 is without pheochromocytoma, type 2 is with pheochromocytoma. VHL type 2 is further subdivided into types 2A (pheochromocytoma, retinal angioma, and hemangioblastomas without renal cell carcinoma and pancreatic cyst) and 2B (pheochromocytoma, retinal angioma, and hemangioblastomas with renal cell carcinoma and pancreatic cyst). VHL type 2C refers to patients with isolated pheochromocytoma without hemangioblastoma or renal cell carcinoma. The estimated incidence is 3/100000 births per year and penetrance is 97% by age 60 years.,Domain:The elongin BC complex binding domain is also known as BC-box with the consensus [APST]-L-x(3)-C-x(3)-[AILV].,Function:Involved in the ubiquitination and subsequent proteasomal degradation via the von Hippel-Lindau ubiquitination complex. Seems to act as target recruitment subunit in the E3 ubiquitin ligase complex and recruits hydroxylated hypoxia-inducible factor (HIF) under normoxic conditions. Involved in transcriptional repression through interaction with HIF1A, HIF1AN and histone deacetylases.,pathway:Protein modification; protein ubiquitination.,subcellular location:Equally distributed between the nucleus and the cytoplasm but not membrane-associated.,subcellular location:Found predominantly in the cytoplasm and with less amounts nuclear or membrane-associated.,subunit:Component of the VCB (VHL-Elongin BC-CUL2) complex; this complex acts as a ubiquitin-ligase E3 and directs proteosome-dependent degradation of targeted proteins. Interacts with CUL2; this interaction is dependent on the integrity of the trimeric VBC complex. Interacts (via the beta domain) with HIF1A (via the NTAD domain); this interaction mediates degradation of HIF1A in normoxia and, in hypoxia, prevents ubiqitination and degradation of HIF1A by mediating hypoxia-induced translocation to the nucleus, a process which requires a hypoxia-dependent regulatory signal. Interacts with RNF139 and UBP33. Interacts with PHF17.,tissue specificity:Expressed in the adult and fetal brain and kidney.,
推荐产品
相关文献
我们始终开放沟通，期待为您提供支持。
我们以一抗、二抗产品为核心，深耕抗体试剂细分领域。依托自主搭建的核心技术平台与专业的研发生产团队，我们为全球高校、科研院所、生物医药企业等客户提供高可靠性的生物试剂产品及全链条技术
支持服务。自成立以来，Pinofibio 始终坚守“以科研需求为导向”的发展理念，通过完善的研发体系、严苛的质量控制与高效的服务响应，致力于构建覆盖多物种、多靶点的抗体产品矩阵，助力科研工作者攻克技术难题，推动生物医药产业的创新发展。
武汉市皮诺飞生物科技有限公司
地址：湖北省武汉市江夏区神墩四路 666 号武汉国英种业大厦A栋14F
邮箱：pinuofei2017@163.com
TEL：15392937510
小红书
实验服务
公众号
抗体服务
微信客服